Zhu Tian-Yu, Hong Lian-Lian, Ling Zhi-Qiang
Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310018, Zhejiang, China.
Biomark Res. 2023 Jun 6;11(1):62. doi: 10.1186/s40364-023-00499-0.
N-methyladenosine (mA) is the most prevalent and well-characterized internal chemical modification in eukaryotic RNA, influencing gene expression and phenotypic changes by controlling RNA fate. Insulin-like growth factor-2 mRNA-binding proteins (IGF2BPs) preferentially function as mA effector proteins, promoting stability and translation of mA-modified RNAs. IGF2BPs, particularly IGF2BP1 and IGF2BP3, are widely recognized as oncofetal proteins predominantly expressed in cancer rather than normal tissues, playing a critical role in tumor initiation and progression. Consequently, IGF2BPs hold potential for clinical applications and serve as a good choice for targeted treatment strategies. In this review, we discuss the functions and mechanisms of IGF2BPs as mA readers and explore the therapeutic potential of targeting IGF2BPs in human cancer.
N6-甲基腺苷（m6A）是真核生物RNA中最普遍且特征明确的内部化学修饰，通过控制RNA的命运影响基因表达和表型变化。胰岛素样生长因子2 mRNA结合蛋白（IGF2BPs）优先作为m6A效应蛋白发挥作用，促进m6A修饰RNA的稳定性和翻译。IGF2BPs，尤其是IGF2BP1和IGF2BP3，被广泛认为是癌胚蛋白，主要在癌症而非正常组织中表达，在肿瘤的发生和发展中起关键作用。因此，IGF2BPs具有临床应用潜力，是靶向治疗策略的良好选择。在这篇综述中，我们讨论了IGF2BPs作为m6A阅读蛋白的功能和机制，并探讨了靶向IGF2BPs在人类癌症中的治疗潜力。
